The use of hydrolytic enzymes as adjuvant therapy in AIDS/ARC/LAS patients.
The purpose of this paper is to discuss a hypothesis corroborating the use of hydrolytic enzymes in AIDS/ARC/LAS patients, showing high levels of circulating immune complexes (CIC). Other diseases, revealing high CIC-levels as well, may be improved or even cured by eliminating CIC. The results obtained from experiences of CIC-elimination by hydrolytic enzymes are presented below. As may be determined from the data available, hydrolytic enzymes should be included in the therapy of HIV-positive patients. Clinical trials are being continued.